The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular edema

被引:12
|
作者
Cicinelli, Maria Vittoria [1 ,2 ]
Rosenblatt, Amir [3 ,4 ]
Grosso, Domenico [2 ]
Zollet, Piero [2 ]
Capone, Luigi [2 ]
Rabiolo, Alessandro [2 ,5 ]
Lattanzio, Rosangela [2 ]
Loewenstein, Anat [3 ,4 ]
Bandello, Francesco [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy
[3] Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham, Glos, England
关键词
VITREOUS INSERTS; MANAGEMENT; RANIBIZUMAB; EFFICACY; BENEFIT; RETINA; 3-YEAR; SAFETY;
D O I
10.1038/s41433-020-01373-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/Objectives To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). Methods Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation >= 5 mmHg or IOP > 21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated-measure design. Results Forty-four eyes of 33 patients were included. Patients were shifted to FAc after a mean +/- standard deviation of 4.6 +/- 3.2 DEX injections. Overall, BCVA and CMT improved during the first 12 months after switching to FAc (p = 0.04 and p < 0.001, respectively). Only eyes with a good morphologic response to DEX had a significant CMT reduction after FAc (p < 0.001), while no significant relationship was found between BCVA improvement after DEX and after FAc. IOP elevation occurred in 9 eyes (20%) following DEX implant. These eyes carried a 20-fold increased risk of having an IOP rise after FAc (p < 0.001), with a non-linear relationship between the IOP increase after DEX and the one after FAc. Conclusion The response to previous DEX may anticipate the morphologic response to subsequent FAc. Eyes with steroid-induced IOP elevation after DEX are at a high risk of IOP increase after FAc. The visual response after FAc was not associated with the visual response to previous steroids, indicating that FAc may have a role also in patients refractory to DEX implant.
引用
收藏
页码:3232 / 3242
页数:11
相关论文
共 50 条
  • [1] The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema
    Maria Vittoria Cicinelli
    Amir Rosenblatt
    Domenico Grosso
    Piero Zollet
    Luigi Capone
    Alessandro Rabiolo
    Rosangela Lattanzio
    Anat Loewenstein
    Francesco Bandello
    Eye, 2021, 35 : 3232 - 3242
  • [2] Correction: The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema
    Maria Vittoria Cicinelli
    Amir Rosenblatt
    Domenico Grosso
    Piero Zollet
    Luigi Capone
    Alessandro Rabiolo
    Rosangela Lattanzio
    Anat Loewenstein
    Francesco Bandello
    Eye, 2021, 35 : 3459 - 3459
  • [3] Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
    Baillif, Stephanie
    Staccini, Pascal
    Weber, Michel
    Delyfer, Marie-Noelle
    Le Mer, Yannick
    Gualino, Vincent
    Collot, Laurence
    Merite, Pierre-Yves
    Creuzot-Garcher, Catherine
    Kodjikian, Laurent
    Massin, Pascale
    PHARMACEUTICS, 2022, 14 (11)
  • [4] Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
    Messenger, Wyatt B.
    Beardsley, Robert M.
    Flaxel, Christina J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 425 - 434
  • [5] Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant
    Ciulla, Thomas A.
    Harris, Alon
    McIntyre, Nathaniel
    Jonescu-Cuypers, Christian
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 953 - 959
  • [6] Treatment of Refractory Diabetic Macular Edema with Intravitreal Injection of a Fluocinolone Acetonide Implant
    Rubino, Shaina M.
    Komanski, Chris Bligh
    John, Vishak J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [7] Clinical Outcomes in Treatment of Diabetic Macular Edema with Fluocinolone Acetonide Intravitreal Implant
    West, Matthew
    Kim, Samuel
    Khanifar, A. A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [8] The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema (Jan, 10.1038/s41433-020-01373-1, 2021)
    Cicinelli, Maria Vittoria
    Rosenblatt, Amir
    Grosso, Domenico
    Zollet, Piero
    Capone, Luigi
    Rabiolo, Alessandro
    Lattanzio, Rosangela
    Loewenstein, Anat
    Bandello, Francesco
    EYE, 2021, 35 (12) : 3459 - 3459
  • [9] Fluocinolone acetonide (Iluvien) extended-release intravitreal implant for diabetic macular edema
    Carle, Michelle V.
    Chu, Thomas G.
    Boyer, David S.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2014, 9 (02) : 81 - 88
  • [10] Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema
    Syed, Yahiya Y.
    DRUGS, 2017, 77 (05) : 575 - 583